DE69819110D1 - Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus - Google Patents

Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus

Info

Publication number
DE69819110D1
DE69819110D1 DE69819110T DE69819110T DE69819110D1 DE 69819110 D1 DE69819110 D1 DE 69819110D1 DE 69819110 T DE69819110 T DE 69819110T DE 69819110 T DE69819110 T DE 69819110T DE 69819110 D1 DE69819110 D1 DE 69819110D1
Authority
DE
Germany
Prior art keywords
ones
lipid metabolism
medicine
treat obesity
improve lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819110T
Other languages
English (en)
Other versions
DE69819110T2 (de
Inventor
Kunio Suzuki
Takeshi Shimizu
Tadashi Nakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN Institute of Physical and Chemical Research
Original Assignee
RIKEN Institute of Physical and Chemical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN Institute of Physical and Chemical Research filed Critical RIKEN Institute of Physical and Chemical Research
Publication of DE69819110D1 publication Critical patent/DE69819110D1/de
Application granted granted Critical
Publication of DE69819110T2 publication Critical patent/DE69819110T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
DE69819110T 1997-11-06 1998-11-06 Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus Expired - Lifetime DE69819110T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP30404997 1997-11-06
JP30404997 1997-11-06
JP23814498 1998-08-25
JP23814498A JP3873097B2 (ja) 1997-11-06 1998-08-25 抗肥満剤及び脂質代謝改善剤

Publications (2)

Publication Number Publication Date
DE69819110D1 true DE69819110D1 (de) 2003-11-27
DE69819110T2 DE69819110T2 (de) 2004-07-15

Family

ID=26533552

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819110T Expired - Lifetime DE69819110T2 (de) 1997-11-06 1998-11-06 Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus

Country Status (6)

Country Link
US (1) US6046184A (de)
EP (1) EP0916342B1 (de)
JP (1) JP3873097B2 (de)
AT (1) ATE252389T1 (de)
CA (1) CA2253130C (de)
DE (1) DE69819110T2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531462B2 (en) * 1997-11-06 2003-03-11 Riken Medicament for treating obesity and improving lipid metabolism
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DE69929177T2 (de) * 1998-03-26 2006-08-24 Phytopharm Plc, Godmanchester Smilagenin und anzurogenin-d zur behandlung der alzheimerischen krankheit
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
JP3790686B2 (ja) * 2001-08-03 2006-06-28 独立行政法人理化学研究所 血糖降下剤
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
WO2003092614A2 (en) * 2002-05-02 2003-11-13 Hickle Randall S Lipid removal from the body
JP4404710B2 (ja) 2004-07-14 2010-01-27 有限会社テクノフローラ ステロールの５−エン−３−オン体の製造方法、及び分析方法
CA2611086C (en) 2005-09-22 2011-06-21 Morinaga Milk Industry Co., Ltd. Agent for inhibiting visceral fat accumulation
RU2419438C2 (ru) 2005-09-22 2011-05-27 Моринага Милк Индастри Ко., Лтд. Средство для ингибирования накопления висцеральной жировой ткани
KR100999317B1 (ko) 2005-09-30 2010-12-09 모리나가 뉴교 가부시키가이샤 인슐린 저항성 개선제
US8236769B2 (en) 2005-09-30 2012-08-07 Morinaga Milk Industry Co., Ltd. Agent for improving insulin resistance
FR2914188B1 (fr) * 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
FR2924346B1 (fr) * 2007-11-30 2010-02-19 Inst Biophytis Sas Utilisation de phytoecdysones dans la preparation d'une composition pour agir sur le syndrome metabolique.
JP2011051939A (ja) * 2009-09-02 2011-03-17 Toyo Hakko:Kk 血中ｈｄｌコレステロール上昇剤、並びにそれを含む飲食品添加剤、飲食品及び医薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
JPH0723310B2 (ja) * 1986-03-03 1995-03-15 株式会社アドバンス 強肝剤
IL94272A (en) * 1989-05-11 1994-04-12 Richter Gedeon Vegyeszet History of A9 Acids - Hydroxy - 3 - Oxo - 4, 42) 52 (- Stigmestadian 62 - Oai, process for their preparation and pharmaceutical preparations containing them
US5264428A (en) * 1990-02-16 1993-11-23 Kanoldt Arzneimittel Gmbh Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
DE4004920C1 (de) * 1990-02-16 1991-09-19 Kanoldt Arzneimittel Gmbh, 8884 Hoechstaedt, De
JP3029907B2 (ja) * 1991-12-20 2000-04-10 理化学研究所 抗肥満剤
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
JP3129367B2 (ja) * 1993-10-08 2001-01-29 日本油脂株式会社 角化亢進抑制剤
AU8257898A (en) * 1997-06-17 1999-01-04 Rutgers, The State University Of New Jersey Hypocholesterolemic compositions from bamboo shoots

Also Published As

Publication number Publication date
CA2253130C (en) 2008-01-15
ATE252389T1 (de) 2003-11-15
JPH11193296A (ja) 1999-07-21
JP3873097B2 (ja) 2007-01-24
EP0916342B1 (de) 2003-10-22
EP0916342A1 (de) 1999-05-19
DE69819110T2 (de) 2004-07-15
CA2253130A1 (en) 1999-05-06
US6046184A (en) 2000-04-04

Similar Documents

Publication Publication Date Title
DE69819110D1 (de) Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
RU94045155A (ru) Способы ингибирования болезни альцгеймера
DE69633613D1 (de) 2-Amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-diol enthaltendes Arzneimittel zur topischen Anwendung zur Behandlung von Erkrankungen die durch eine Störung des Immunsystems hervorgerufen werden
AU2002357311A1 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE162073T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose enthaltend xanthohumol
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69930624D1 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
EP0324348A3 (de) Piperidincarboxamid-Derivate zur Behandlung von Bradycardien und Bradyarrhythmien
NO961496L (no) Behandling av allergiske sykdommer med terfenadinkarboksylat
IT1251993B (it) Composizioni farmaceutiche ad uso orale,a base di esteri di gangliosidi,per il trattamento di neuropatie del sistema nervoso periferico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition